shape therapeutics leadership teamnorth walsham police station telephone number
Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . Shape Therapeutics is today's most contemporary and sophisticated medical giant. 10% of PTC Therapeutics management is Hispanic or Latino. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. Get the full list, Youre viewing 5 of 9 board members. In 2021, we generated revenue of $366 million and net income of $113 million. The company closed a series B financing led by . Shape Life! We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Powered by Madgex Job Board Software. John C. Martin, Ph.D., was elected to our Board in January 2020. | Source: San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. It focuses on RNA-editing gene therapy. By continuing to use this site you are consenting to these choices. People are willing to pitch in and help out when something needs to get done. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. You can read more about your cookie choices at our privacy policyhere. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . ", Im here to bring genetic medicine to life. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. Headquarters Location 219 Terry Ave N Suite 100 Developer of RNA-targeted therapies intended to treat challenging diseases. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Shape Therapeutics, Inc. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Our Story. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Get started with your Free Employer Profile, Work Here? Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics Cindy Fung, PhD At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. Get contact details including emails and phone numbers We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. . A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss Existing Subscriber? Operating Status Active. Sign up for a free account. Learn more. There isnt a path to guide us. Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Discover current leadership team members including founders, CEO, other executives and board directors. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . Shape Therapeutics's Vice President, Head of Research is David Huss. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Rznomics was founded in 2017 and is based in Yongin-si, South Korea. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. our sites and services. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Highlight your management teams expertise. Shape Life! Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. Shape Therapeutics's founder is Prashant Mali. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . Shape Therapeutics, Inc. employs 14 employees. Operator. We [] The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Shape Therapeutics Inc. Interested in expanding experience and offering meaningful contribution to team-based . Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Its very rewarding. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. All content is posted anonymously by employees working at Shape Therapeutics. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. All rights reserved. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. {{ userNotificationState.getAlertCount('bell') }}. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. We have to be creative; we need to transform the paradigm. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, CBI websites generally use certain cookies to enable better interactions with our sites and services. Interested in researching Shape Therapeutics? Shape Life! from Harvard Law School. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. See what employees say it's like to work at Shape Therapeutics. Chief Scientific Officer, Francois Vigneault Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. 11 Shape Therapeutics reviews. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. 219 Terry Avenue North it is imperative the team flawlessly execute a launch plan aligned with brand strategy. Im thrilled to join such a talented team of innovative thinkers. ProQR Therapeutics Shape Therapeutics's key executives include David Huss and 11 others. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). 56% of the management team is White. This is a profile preview from the PitchBook Platform. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. Last Funding Type Series B. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. April 20, 2021 08:00 ET She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Working at Shape has been great! Investors & Media Shape Therapeutics is a development-stage biotechnology company. site you are consenting to these choices. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. I cannot imagine being anyplace else.". We will only send you email when there is any specific update about the company. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Great team culture. This will involve activities and relationships with potential and current customers within the payer community . ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Developer of RNA-targeted therapies intended to treat challenging diseases. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. July 15, 2021 08:00 ET Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. 2023 Sarepta Therapeutics, Inc. All rights reserved. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. You can read more about your. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. . Shape Life!